Head-to-head comparison of thymoglobulin [antithymocyte globulin] vs. [versus] campath-1h [alemtuzumab] vs. our standard center treatment [daclizumab] protocol in living donor renal transplantation - a study to evaluate the avoidance of long-term nephrotoxic calcineurin inhibitor therapy.

Trial Profile

Head-to-head comparison of thymoglobulin [antithymocyte globulin] vs. [versus] campath-1h [alemtuzumab] vs. our standard center treatment [daclizumab] protocol in living donor renal transplantation - a study to evaluate the avoidance of long-term nephrotoxic calcineurin inhibitor therapy.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Nov 2010

At a glance

  • Drugs Alemtuzumab; Antithymocyte globulin; Daclizumab
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Jan 2010 Actual end date changed from Oct 2007 to Dec 2008 as reported by ClinicalTrials.gov.
    • 13 Jan 2010 Actual end date changed from Oct 2007 to Dec 2008 as reported by ClinicalTrials.gov.
    • 09 Jun 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top